<DOC>
	<DOCNO>NCT00353119</DOCNO>
	<brief_summary>Palmoplantar pustulosis ( PPP ) chronic recurrent skin condition characterize presence pustule , erythema hyperkeratosis palm sol . PPP severe disable disease limit ability walk work . Although study quality life patient PPP available , recent investigation show palmoplantar psoriasis ( non pustular ) important impact quality life plaque psoriasis . This important impact quality life surprising palmoplantar psoriasis well palmoplantar pustulosis may limit ability work conduct activity hand even impair walk . The disease sometimes associate psoriasis elsewhere body . Current treatment PPP include topical corticosteroid , cyclosporine , PUVA therapy , methotrexate acitretin . Response topical corticosteroid PUVA therapy often disappointing presumably thickness stratum corneum palm sole prevents good penetration topical medication light . Cyclosporine methotrexate sometimes use success PPP concern long term toxicity drug . Therefore need new treatment PPP .</brief_summary>
	<brief_title>A Placebo-Controlled Double-Blind Study Safety Efficacy Etanercept Palmoplantar Pustulosis</brief_title>
	<detailed_description>This placebo-controlled double blind study . Patients randomize receive etanercept versus placebo 2:1 fashion first 3 month . All patient receive etanercept last 3 month . Patients active PPP include . A washout 4 week systemic medication 2 week Psoralen Ultra Violet A ( PUVA ) therapy require . A washout period 2 week require topical medication . The Palmoplantar pustulosis severity index ( PPPASI ) use evaluate severity . Only patient severity score 8 hand and/or foot include . Safety assess perform physical examination , evaluation adverse event biological parameter ( complete blood count ( CBC ) , chemistry , urinalysis ) . High quality digital medical photograph take baseline , 3 month 6 month .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Palmoplantar pustulosis severity score least 8 hand andor foot Age 18 year old Patient would benefit systemic therapy Unless surgically sterile ( least 1 year postmenopausal woman ) patient ( heterosexual men woman ) must use effective method contraception least 30 day start study drug least 1 month last drug administration Informed consent obtain Normal non clinically significant chest X ray take within 6 month screen Negative serum pregnancy test screen negative urine pregnancy test day 0 woman childbearing potential Negative personal history tuberculosis Presence PPP 6 month Subject must willing inject subcutaneously . Negative PPD result Use topical steroid , topical tar preparation , topical anti PPP antipsoriatic preparation within past two week Unstable form psoriasis ( acute guttate psoriasis , psoriatic erythroderma , generalize pustular psoriasis ) At investigator 's discretion significant infection within 30 day screen patient risk septicemia Presence acute form tinea pedis cause pustular eruption palm sol apart PPP base clinical evaluation Evidence skin condition would interfere evaluation PPP Use investigational drug within past four week Use systemic antiPPP antipsoriatic drug steroid , retinoids , methotrexate within past four week Use parenteral systemic antibiotic within past four week Use cyclosporine within past four week Use ultraviolet light therapy ( UVB , nbUVB PUVA ) within past two week An unstable serious medical condition Known seropositivity HIV virus Known hypersensitivity etanercept one component Receipt live attenuate vaccine 12 week less Day 0 course study Pregnant breast feed female subject Any significant medical condition might cause study detrimental patient At investigator 's discretion current history alcohol drug abuse would interfere ability comply study protocol Presence congestive heart failure Presence demyelinating disorder ( optic neuritis , multiple sclerosis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Palmoplantar pustulosis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Etanercept</keyword>
</DOC>